MEDI0382, a GLP ‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study
British Journal of Clinical Pharmacology, EarlyView.
Source: British Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Philip D.Ambery
,
SebastianKlammt
,
Maximillian G.Posch
,
MarcellaPetrone
,
WenjiPu
,
CristinaRondinone
,
LutzJermutus
,
BoazHirshberg Source Type: research